Granted Patent
B2
US 12,383,525 · App. 17/614,294 · Granted Aug 12, 2025
Compositions comprising cetylated fatty acids and use thereof for the treatment of arthritis and joint inflammatory conditions
Assignee:
PHARMANUTRA S.P.A.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and an antioxidant in reduced percentages by weight, and related methods for treatment of arthritis and of inflammatory joint and musculoskeletal pain. Furthermore composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and, optionally, an antioxidant, and related treatment methods for protecting the gastric mucosa and for regulating the blood glucose levels. Additionally, a method is described for preparing the at least one cetylated fatty acid or mixture of cetylated fatty acids and for preparing compositions comprising the cetylated fatty acids and the antioxidant.
Claims (35)
1. A composition comprising a mixture of:
(a) at least one cetylated fatty acid wherein said fatty acid is a saturated or unsaturated fatty acids having a number of carbons from C6 to C21, wherein said at least one cetylated fatty acid is a mixture of cetylated fatty acids comprising, cetylated myristic acid and cetylated oleic acid, and
(b) at least one antioxidant at a % by weight from 0.001% to 0.3% with respect to the total weight of the composition, wherein the at least one antioxidant is selected from
(i) tert-butyl-hydroquinone (TBHQ),
(ii) a mixture comprising tocopherol, lecithin, ascorbyl palmitate and citric acid,
(iii) a tocopherol or a mixture of tocopherols and a natural rosemary extract,
(iv) butylated hydroxytoluene, and
(v) mixtures thereof,
wherein the composition further comprises
(c) a vegetable oil selected from olive oil, corn oil, sunflower oil with high oleic content and mixtures thereof; and
wherein the composition optionally further comprises at least one food or pharmaceutical grade additive and/or excipient.
2. The composition according to claim 1 , wherein said mixture of cetylated fatty acids further comprises cetylated linoleic acid and cetylated palmitic acid.
3. The composition according to claim 1 , wherein said at least one antioxidant is present at a % by weight from 0.001% to 0.1% with respect to the total weight of the composition.
4. The composition according to claim 1 , wherein the mole ratio between said cetylated myristic acid and cetylated oleic acid is from 4:1 to 1:1.
5. The composition according to claim 1 , wherein said composition comprises:
said at least one cetylated fatty acid, at a % by weight from 50% to 90% with respect to the total weight of the composition; and
said vegetable oil at a % by weight from 9.5% to 50% with respect to the total weight of the composition.
6. A method for preventive and/or curative and/or symptomatic treatment of a subject in need thereof, the method comprising
administering to the subject the composition according to claim 1 to provide the preventive curative and/or symptomatic treatment to the subject, of arthritis, inflammatory joint and musculoskeletal conditions, protection of the gastric mucosa of the individual and/or regulation of blood glucose levels, of the individual.
7. The method according to claim 6 , wherein said composition is administered for preventive and/or curative and/or symptomatic treatment of (i) rheumatoid arthritis of inflammatory and non-inflammatory origin; (ii) joint inflammatory conditions other than rheumatoid arthritis; (iii) psoriasis, lupus, periodontal diseases or cardiovascular or heart diseases; (iv) post-traumatic osteoarticular and musculoskeletal diseases including sports-related traumas and athletic pubalgia; (v) degenerative joint diseases, and/or (vi) tendon and muscle-related inflammatory/traumatic conditions.
8. The composition according to claim 1 , wherein said composition is formulated for oral use.
9. The composition according to claim 1 , wherein said composition is formulated for topical or transdermal use.
10. The composition according to claim 1 , wherein said composition is a novel food or a food or a beverage or a dietary supplement or a food or a beverage or a dietary supplement composition.
11. The composition according to claim 1 , wherein said composition is a pharmaceutical composition or a medical device composition.
12. The composition according to claim 1 , wherein said at least one antioxidant is selected from tert-butyl-hydroquinone (TBHQ) or a tocopherol or a mixture of tocopherols.
13. The composition according to claim 4 , wherein the mole ratio between said cetylated myristic acid and cetylated oleic acid is from 3:1 to 1.5:1.
14. The composition according to claim 1 , wherein said vegetable oil is olive oil.
15. The composition according to claim 5 , wherein said composition comprises:
said at least one cetylated fatty acid, at a % by weight from 60% to 85% with respect to the total weight of the composition.
16. The composition according to claim 5 , wherein said composition comprises said antioxidant at a % by weight from 0.005% to 0.1%, with respect to the total weight of the composition.
17. The composition according to claim 5 , wherein said composition comprises said vegetable oil at a % by weight from 14.5% to 40%, with respect to the total weight of the composition.
18. The composition according to claim 1 , wherein the mixture comprising tocopherol, lecithin, ascorbyl palmitate and citric acid comprises α-tocopherol 10-15% by weight, lecithin>50% by weight, ascorbyl palmitate 8-10% by weight and citric acid<1% by weight.
19. The method according to claim 6 , wherein said composition is administered for preventive and/or curative and/or symptomatic treatment of osteoarthritis, gonarthrosis, and coxarthrosis.
20. The method according to claim 6 , wherein said composition is administered for protection of the gastric mucosa of the individual.
21. The method according to claim 6 , wherein said composition is administered to provide regulation of blood glucose levels of the individual.
Assignments (3)
MERGER
Recorded Jul 22, 2025
From: ALESCO S.R.L.; PHARMANUTRA S.P.A.
To: PHARMANUTRA S.P.A.
Reel/Frame 072168/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 4, 2022
From: LACORTE, ANDREA; TARANTINO, GERMANO; BRILLI, ELISA
To: ALESCO S.R.L.; PHARMANUTRA S.P.A.
Reel/Frame 058894/0596 →
Priority Claims (1)
IT 102019000007326
· May 27, 2019
· national
Continuity (1)
References Cited (201)
US 4113881A
· Diehl
· 1978
[cited by applicant]
US 4393133A
· Knowles et al.
· 1983
[cited by applicant]
US 5888563A
· Mehansho et al.
· 1999
[cited by applicant]
US 6039978A
· Bangs et al.
· 2000
[cited by applicant]
US 6361800B1
· Cooper et al.
· 2002
[cited by applicant]
US 6417227B1
· Lord et al.
· 2002
[cited by applicant]
US 8404745B2
· Barathur et al.
· 2013
[cited by applicant]
US 9861670B2
· Clements et al.
· 2018
[cited by applicant]
US 20020058705A1
· Gonzales Bravo et al.
· 2002
[cited by applicant]
US 20050100636A1
· Botteri et al.
· 2005
[cited by applicant]
US 20070148258A1
· O'Neill et al.
· 2007
[cited by applicant]
US 20090186939A1
· Chan et al.
· 2009
[cited by applicant]
US 20100021573A1
· Gonzalez et al.
· 2010
[cited by applicant]
US 20110054030A1
· Petraglia et al.
· 2011
[cited by applicant]
US 20110294665A1
· Makino
· 2011
[cited by applicant]
US 20130157974A1
· Ziegler et al.
· 2013
[cited by applicant]
US 20140121156A1
· Hausman
· 2014
[cited by applicant]
US 20140322314A1
· Fawzy et al.
· 2014
[cited by applicant]
US 20160310445A1
· Vermeer
· 2016
[cited by applicant]
US 20170056465A1
· Tobin et al.
· 2017
[cited by applicant]
US 20170112178A1
· Perrin et al.
· 2017
[cited by applicant]
US 20170202802A1
· Fernandez et al.
· 2017
[cited by applicant]
US 20200206157A1
· Lacorte et al.
· 2020
[cited by applicant]
US 20220226274A1
· Lacorte et al.
· 2022
[cited by applicant]
CN 106343566A
· 2017
[cited by applicant]
CN 108137472A
· 2018
[cited by applicant]
EP 0679394A2
· 1995
[cited by applicant]
EP 2380578A1
· 2011
[cited by applicant]
EP 2886129A1
· 2015
[cited by applicant]
GB 2552952A
· 2018
[cited by applicant]
JP S5841813A
· 1983
[cited by applicant]
JP H08253415A
· 1996
[cited by applicant]
JP 2002515866A
· 2002
[cited by applicant]
JP 2003342159A
· 2003
[cited by applicant]
JP 2007523056A
· 2007
[cited by applicant]
JP 2009525277A
· 2009
[cited by applicant]
JP 2015523409A
· 2015
[cited by applicant]
NZ 332959A
· 2001
[cited by applicant]
WO 9731620A2
· 1997
[cited by applicant]
WO 0064436A1
· 2000
[cited by applicant]
WO 03018731A1
· 2003
[cited by applicant]
WO 2004019923A1
· 2004
[cited by applicant]
WO 2004084829A2
· 2004
[cited by applicant]
WO 2004084829A3
· 2005
[cited by applicant]
WO 2005044189A2
· 2005
[cited by applicant]
WO 2007089577A2
· 2007
[cited by applicant]
WO 2010079514A1
· 2010
[cited by applicant]
WO 2010117194A2
· 2010
[cited by applicant]
WO 2012161572A1
· 2012
[cited by applicant]
WO 2014009806A1
· 2014
[cited by applicant]
WO 2014160279A1
· 2014
[cited by applicant]
WO 2016131993A2
· 2016
[cited by applicant]
WO 2017029580A1
· 2017
[cited by applicant]
WO 2018034797A1
· 2018
[cited by applicant]
WO 2018221534A1
· 2018
[cited by applicant]
WO 2019021232A1
· 2019
[cited by applicant]
WO 2019025922A1
· 2019
[cited by applicant]
WO 2020240438A1
· 2020
[cited by applicant]
WO 2020240441A1
· 2020
[cited by applicant]
WO 2020240443A1
· 2020
[cited by applicant]
Barot, B.S. et al. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study. Pharmaceutical Development and Technology. (Published online May 23, 2013) 19 (5): 513-520. 9 pages.
[cited by applicant]
First Notification of Office Action for Chinese Application No. 202080039453.9 on behalf of Alesco S.R.L Pharmanutra S.P.A. Issued on Feb. 3, 2024. 3 pages. English translation only.
[cited by applicant]
First Notification of Office Action for Chinese Application No. 202080039600.2 on behalf of Alesco S.R.L Pharmanutra S.P.A. Issued on Feb. 2, 2024. 10 pages. Original and English translation.
[cited by applicant]
Gomez-Ramirez, Susana et al. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals. (2018). 11, 97. 23 pages. DOI:10.3390/ph11040097. Website: mdpi.com/journal/pharmaceutical.
[cited by applicant]
Search Report from The Intellectual Property Office of Singapore for Application No. 11202112774X filed on May 27, 2020. Mailed on Aug. 17, 2023. 2 pages. Issued in English.
[cited by applicant]
Search Report from The Intellectual Property Office of Singapore for Application No. 11202112779Y filed on May 27, 2020. Mailed on Aug. 17, 2023. 2 pages. Issued in English.
[cited by applicant]
The Eurasian Patent Office Application No. 202193083/28, Conclusion on patentability of the invention. Mailed on Dec. 19, 2022. 11 pages. Russian and partial English translation.
[cited by applicant]
The Eurasian Patent Office Application No. 202193083/28, Conclusion on patentability of the invention. Mailed on Jul. 19, 2023. 18 pages. Russian and partial English translation.
[cited by applicant]
Wikipedia, The Free Encyclopedia, “Pourbaix diagram”, (Dec. 11, 2017). Downloaded on Mar. 29, 2024. 8 pages.
[cited by applicant]
Wikipedia, The Free Encyclopedia, “Sucrose”, (Dec. 31, 2017). Downloaded on Mar. 29, 2024. 24 pages.
[cited by applicant]
Wikipedia, The Free Encyclopedia, “Sucrose esters”, (Nov. 16, 2017). Downloaded on Mar. 29, 2024. 7 pages.
[cited by applicant]
Written Opinion from The Intellectual Property Office of Singapore for Application No. 11202112774X filed on May 27, 2020. Mailed on Aug. 21, 2023. 7 pages. Issued in English.
[cited by applicant]
Written Opinion from The Intellectual Property Office of Singapore for Application No. 11202112779Y filed on May 27, 2020. Issued on Aug. 21, 2023. 7 pages. Issued in English.
[cited by applicant]
Fragala M.S. et al: “Influences of a dietary supplement in combination with an exercise and diet regimen on adipocytokines and adiposity in women who are overweight”, European Journal Of Applied Physiology, vol. 105, No…
[cited by applicant]
International Search Report for International Application No. PCT/IB2020/055028 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Sep. 9, 2020 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/IB2020/055031 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Aug. 28, 2020 5 pages.
[cited by applicant]
International Search Report for International Application No. PCT/IB2020/055037 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Sep. 10, 2020 4 pages.
[cited by applicant]
Written Opinion for International Application No. PCT/IB2020/055028 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Sep. 9, 2020 6 pages.
[cited by applicant]
Written Opinion for International Application No. PCT/IB2020/055031 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Aug. 28, 2020 8 pages.
[cited by applicant]
Written Opinion for International Application No. PCT/IB2020/055037 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Sep. 10, 2020 5 pages.
[cited by applicant]
Notice of Reasons for Refusal for Japanese Application No. 2021-570463 filed May 27, 2020. Mailed on May 7, 2024. Original and Machine translation. 13 pages.
[cited by applicant]
Commission Directive 96/77/EC of Dec. 2, 1996; last amendment M7 Commission Directive 2006/129/EC of Dec. 8, 2006. 165 pages.
[cited by applicant]
Cutcliffe T et al., “Vitamin K2 may reverse calcification of blood vessels in people with kidney disease”
[cited by applicant]
E322-Lechitins: on the web site of INCHEM (Internationally Peer Reviewed Chemical Safety Information), World Health Organization, the following Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on F…
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/635,516, filed Jan. 30, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Dec. 1, 2021 15 pages.
[cited by applicant]
Ilbert, Marianne et al., “Review: Insight into the evolution of the iron oxidation pathways”, Biochimica et Biophysica Acta, 1827 (2013), pp. 161-175.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2018/055586 filed on Jul. 26, 2018 on behalf of Pharmanutra S.P.A. Mail Date: Jan. 28, 2020 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2018/055634 filed on Jul. 27, 2018 on behalf of Pharmanutra S.P.A. Mail Date: Feb. 4, 2020 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2020/055028 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Nov. 16, 2021 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2020/055031 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Nov. 16, 2021 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2020/055037 filed on May 27, 2020 on behalf of Alesco S.R.L. Mail Date: Nov. 16, 2021 6 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2018/055586 filed on Jul. 26, 2018 on behalf Pharmanutra S.P.A. Mail Date: Oct. 25, 2018 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2018/055634 filed on Jul. 27, 2018 on behalf Pharmanutra S.P.A. Mail Date: Dec. 4, 2018 12 pages.
[cited by applicant]
Kidney disease—
[cited by applicant]
Muriuki J.M. et al., “Malaria is a cause of iron deficiency in African children”
[cited by applicant]
Neven E. et al., “Iron and vascular calcification. Is there a link”
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/631,426, filed Jan. 15, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Nov. 10, 2021 17 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/635,516, filed Jan. 30, 2020 on behalf of Pharmanutra S.P.A. Mail Date: May 12, 2021 30 pages.
[cited by applicant]
Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Material in Contact with Food on Sucrose esters of fatty acids, e 473 and sucroglycerides, E 474 based on a request from the Commission…
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 16/631,426, filed Jan. 15, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Aug. 20, 2021 10 pages.
[cited by applicant]
Spiegel D.M. et al., “Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study”
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/631,426, filed Jan. 15, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Nov. 16, 2023. 17 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/635,516, filed Jan. 30, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Oct. 4, 2023. 25 pages.
[cited by applicant]
Shah, R.B. et al., “Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: Iron sucrose”, International Journal of Pharmaceutics, 464 (Jan. 17, 2014), pp. 46-52.
[cited by applicant]
Advisory Action for U.S. Appl. No. 16/631,426, filed Jan. 15, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Dec. 20, 2022. 4 Pages.
[cited by applicant]
Aoun, M. et al. “High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial”, BMC Nephrology, Jun. 2017, vol. 18, 191. 10 pages.
[cited by applicant]
Barisani et al. “Iron overload and gene expression in HepG2 cells: analysis by differential display”
[cited by applicant]
Barpanda P et al. “Sodium iron pyrophosphate: a novel 3.0V iron-based cathode for sodium-ion batteries”, Electrochemistry Communications, vol. 24, Oct. 2012, pp. 116-119.
[cited by applicant]
Breymann, Prof. Dr. Christian. Preventing and Treating Iron Deficiency Anaemia in Pregnant Women. Are we doing our best? Presentation in Zurich, Switzerland, May 15, 2017. 27 pages.
[cited by applicant]
Chung, B. et al. “Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone”,
[cited by applicant]
Commission Regulation (EU) No. 231/2012 of Mar. 9, 2012. Specifications for food additives listed on Annexes II and III to Regulation (EC) No. 1333/2008 of the European Parliament and of the Council. Official Journal of…
[cited by applicant]
“Coordination Complex” from Wikipedia, through the Wayback Machine dated Nov. 18, 2016. 10 pages.
[cited by applicant]
The Regulation (EC) No. 1333/2008 of the European Parliament and of the Council of Dec. 16, 2008 on food additives. Dated: Mar. 22, 2023. pp. 346.
[cited by applicant]
Decision of Rejection for Japanese Application No. 2020-502672 filed on Jul. 26, 2018 on behalf of Pharmanutra S.P.A. Dated Jan. 4, 2023. 9 pages.
[cited by applicant]
Erni, I. Oswald N. et al. “Chemical characterization of iron (III)-hydroxide-dextrin complexes. A comparative study of commercial preparations with alleged reproductions used in the examination of bioavailability”, Arzn…
[cited by applicant]
EUR-Lex, Access to European Union Law, Document 51977PC0304. Proposal for a Council Directive amending for the first time Directive 74/329/EEC on the approximation of the laws of the Member States relating to emulsifier…
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/631,426, filed Jan. 15, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Aug. 11, 2022. 18 Pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/635,516, filed Jan. 30, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Feb. 22, 2023. 18 pages.
[cited by applicant]
Firdaus S et al. “Green synthesis of silver nanoparticles using Carica Papaya fruit extract under sunlight irradiation and their colorimetric detection of mercury ions”, 2nd International Symposium on Frontier of Applie…
[cited by applicant]
“Food additives” from European Food Safety Authority, Downloaded Jul. 21, 2023. 9 pages. Website: www.efsa.europa.eu/en/topics/topic/food-additives.
[cited by applicant]
“Food additives” from European Food Safety Authority (EFSA), Downloaded though The Wayback Machine for Jul. 17, 2017. 2 pages. Website: www.efsa.europa.eu/en/topics/topic/food-additives.
[cited by applicant]
Garrelds, I. M. et al. “Time dependent production of cytokines and eicosanoids by human monocytic leukaemia U937 cells; effects of glucocorticosteroids”
[cited by applicant]
Geisser, P. et al. Review: The Pharmacokinetics and Pharmacodynamics of Iron Preparations. Pharmaceutics, (Jan. 2011) 3, pp. 12-33. Doi.org/10.3390/pharmaceutics3010012. Website: mdpi.com/journal/pharmaceutics.
[cited by applicant]
Geisser, Peter. Safety and Efficacy of Iron(III)-hydroxide Polymaltose Complex. Arzneimittel-Forschung (Drug Research) 2007: 57 (6a): 439-452.
[cited by applicant]
Gupta A., et al. “Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis” Kidney International (1999); 55(5):1891-1898.
[cited by applicant]
Huang, Z.B. et al. “HMGB1 release by human liver L02 and HepG2 cells induced by lipopolysaccharide”
[cited by applicant]
“Iron Dextran” from DrugBank, DrugBank Accession No. DB00893, dated Nov. 26, 2022, 14 pages.
[cited by applicant]
“Iron polymaltose” from Wikipedia, Downloaded: Jul. 23, 2023. 5 pages. Website: en.wikipedia.org/wiki/Iron_polymaltose.
[cited by applicant]
“Iron Sucrose” from Wikipedia, through the Wayback Machine dated Oct. 22, 2016. 1 page.
[cited by applicant]
Liu, H.Z. et al. “The U937 cell line induced to express CD14 protein by 1,25-dihydroxyvitamin D3 and be sensitive to endotoxin stimulation”
[cited by applicant]
McCarty, M.F. et al. “Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binder, niacin, and avoidance of phosphate additives”, Nutrition, (Jul.-Aug.…
[cited by applicant]
Miki, K. et al. “Extracellular activation of arginase-1 decreases enterocyte inducible nitric oxide synthase activity during systemic inflammation”
[cited by applicant]
Nicoll, R. et al. “A Review of the Effect of Diet on Cardiovascular Calcification”, Int. J. Mol. Sci., (2015), vol. 16, pp. 8861-8883. ISSN 0004771926.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/631,426, filed Jan. 15, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Feb. 2, 2023. 17 Pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/635,516, filed Jan. 30, 2020 on behalf of Pharmanutra S.P.A. Mail Date: Jul. 26, 2022 18 pages.
[cited by applicant]
O'Neill, W.C. et al. “Plasma pyrophosphate and vascular calcification in chronic kidney disease”, Nephrol Dial Transplant (2010), 25: 187-191. Doi: 10.1093/ndt/gfp362.
[cited by applicant]
O'Neill, W.C. et al. “Treatment with pyrophosphate inhibits uremic vascular calcification”, Kidney Int, Mar. 2011, 76(5): 512-517. 15 pages. Doi: 10.1038/ki.2010.461.
[cited by applicant]
Ozcelik, Berrin. “Fungi/Bactericidal and Static Effect of Ultraviolet Light in 254 and 354 nm wavelengths”
[cited by applicant]
Pepys, M. et al., C-reactive protein: a critical update
[cited by applicant]
Rincon, M. “Interleukin-6: from an inflammatory marker to a target for inflammatory diseases”
[cited by applicant]
Saliou, C. et al. “Selective inhibition of NF-KB activation by the flavonoid hepatoprotector silymarin in HepG2, Evidence for different activating pathways”
[cited by applicant]
“Salt (chemistry)” from Wikipedia, through the Wayback Machine dated Feb. 11, 2016. 4 pages.
[cited by applicant]
Search of Search Food Additives Database for “E473” from European Food Safety Authority, Downloaded Jul. 21, 2023. 3 pages. Website: food.ec.europa.eu/safety/food-improvement-agents/additives/database_en.
[cited by applicant]
Shelley, C. S. et al. “During Differentiation of the Monocytic Cell Line U937, PurAlpha Mediates Induction of the CD11c Beta2 Integrin Gene Promoter”
[cited by applicant]
SiderAL product page on Pharmanutra website. 2 pages. Printed Jul. 21, 2023. Website: www.pharmanutra.it/en/brand/pharmanutra/sideral/.
[cited by applicant]
Sideral.it website. Printed May 19, 2023. 11 pages.
[cited by applicant]
Smith, E. M.; Tangpricha, V. “Vitamin D and Anemia: Insights into an Emerging Association”. Curr Opin Endocrinol Diabetes Obes, Dec. 2015, 22(6), 432-438. 14 pages.
[cited by applicant]
Sonou, T. et al., “Magnesium prevents phosphate-induced vascular calcification via TRPM7 and Pit-1 in an aortic tissue culture model”. Hypertension Research, (2017), vol. 40, pp. 562-567. ISSN 0004771924.
[cited by applicant]
Strober W. “Trypan blue exclusion test of cell viability”
[cited by applicant]
Toblli, J.E. et al., Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia. Review and Meta-analysis. Arzneimittel-Forschung (Drug Research) 2007: 57 (6a): 431-438.
[cited by applicant]
Villarroel P. et al. “Interleukin 6 and lipopolysaccharide modulate hepcidin mRNA expression by HepG2 cells” Biol Trace Elem Res. Dec. 2012;150(1-3):496-501.
[cited by applicant]
Wikipedia page for “International Numbering System for Food Additives” dated Dec. 22, 2016 (16 pp).
[cited by applicant]
Wikipedia page for “E number” dated Jul. 17, 2017 (29 pp).
[cited by applicant]
Zughaier, S.M. et al. “The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes”
[cited by applicant]
Bagirova, V.L. et al. (1998) No. 6. C. 34-36. Russian original + English extract. 8 pages. (D6).
[cited by applicant]
Birrell M. A. et al., “Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype”
[cited by applicant]
Buthelezi N. M. D. et al., “Destructive and non-destructive techniques used for quality evaluation of nuts: A review”
[cited by applicant]
Cho J. et al., “Prostaglandin E2 Induces IL-6 and IL-8 Production by the EP Receptors/Akt/NF-KB Pathways in Nasal Polyp-Derived Fibroblasts”
[cited by applicant]
“Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels: Guidance for Industry”, U.S. Dept of Health and Human Services, Food and Drug Administration, Cente…
[cited by applicant]
“E number” from European Food Safety Authority, Downloaded Jul. 21, 2023. 1 page. Website: www.efsa.europa.eu/en/glossary/e-number#:˜:text=A%20number%20used%20in%20the,has%20been%20apprvoed%20for%20use.
[cited by applicant]
European Food Safety Authority (EFSA), Scientific Opinion on the Safety of ‘Cetyl Myristoleate Complex’ as a food ingredient. 8 (7), 1686 (2010). 14 pages.
[cited by applicant]
First Notification of Office Action for Chinese Application No. 202080039535.3 on behalf of Alesco S.R.L Pharmanutra S.P.A. Issued on Feb. 2, 2024. 9 pages. Original + English translation.
[cited by applicant]
Hinson R. G. et al., “Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2”
[cited by applicant]
Liu X.-H. et al., “Cross-Talk between the Interleukin-6 and Prostaglandin E2 Signaling systems Results in Enhancement of Osteoclastogenesis through Effects on the Osteoprotegerin/Receptor Activator of Nuclear Factor-KB …
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/614,294, filed Nov. 24, 2021 on behalf of Alesco S.R.L. et al. Mailed on Aug. 28, 2024. 23 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/613,719, filed Nov. 23, 2021 on behalf of Alesco S.R.L. et al. Mailed on Sep. 18, 2024. 28 pages.
[cited by applicant]
Non-Final Office Action issued for U.S. Appl. No. 17/613,886, filed Nov. 23, 2021 on behalf of Alesco S.R.L. and Pharmanutra S.P.A. Mailed on Aug. 1, 2024. 25 pages.
[cited by applicant]
Office Action Summary (Examination Result) for United Arab Emirates Application No. P6002147/2021 filed on Nov. 24, 2021. 5 pages (Aug. 6, 2024).
[cited by applicant]
“Peroxide value” from Wikipedia, through The Wayback Machine, Archive Date: Apr. 24, 2017, 2 pages.
[cited by applicant]
Search Report for United Arab Emirates Application No. P6002147/2021 filed on Nov. 24, 2021. 2 pages (Aug. 6, 2024).
[cited by applicant]
Shimoyama, Challenges to Unravel Mechanisms of GERD. Gastroesophageal Reflux Disease. Theory and Research. (Nov. 2018).
[cited by applicant]
Ulatowski, L.M. et al., Vitamin E and neurodegeneration. Neurobiology of Disease, 84 (Dec. 2015), 78-83.
[cited by applicant]
Wautier J. et al., “Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review”
[cited by applicant]
Basson, M.D. Hierarchies of Healing in Gut Mucosal Injury. Journal of Physiology and Pharmacology, (2017), 68, 6, 789-795.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/613,719, filed Nov. 23, 2021 on behalf of Alesco S.R.L. et al. Mailed on Feb. 18, 2025. 19 pages.
[cited by applicant]
Notice of Allowance issued for U.S. Appl. No. 17/613,886, filed Nov. 23, 2021 on behalf of Alesco S.R.L. and Pharmanutra S.P.A. Mailed on Jan. 8, 2025. 10 pages.
[cited by applicant]
Pignitter, M. and Somoza, V.; Critical Evaluation of Methods for the Measurement of Oxidative Rancidity in Vegetable Oils. Journal of Food and Drug Analysis, vol. 20, No. 4, (2012), pp. 772-777. DOI:10.6227/jfda.2012200…
[cited by applicant]
Podolsky, D.K. Mucosal Immunity and Inflammation V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. The American Physiological Society, (1999), 277.3, G495-G499.
[cited by applicant]
Second Notification of Office Action for Chinese Application No. 202080039535.3 on behalf of Alesco S.R.L Pharmanutra S.P.A. Issued on Nov. 6, 2024. 10 pages. Original + English translation.
[cited by applicant]
Wallace, John L., Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?, Physiol. Rev, 88, (2008), 1547-1565.
[cited by applicant]
Wikipedia page for “Gastric mucosal barrier”. Retrieved for Dec. 22, 2016 through The Wayback Machine.
[cited by applicant]
World Health Organization, Eastern Mediterranean Region: Health promotion and disease prevention through population-based interventions, including action to address social determinants and health inequality. Retrieved f…
[cited by applicant]
World Health Organization, Eastern Mediterranean Region: Health promotion and disease prevention through population-based interventions, including action to address social determinants and health inequality. Retrieved o…
[cited by applicant]
Yang, Ines et al., Survival in hostile territory: the microbiota of the stomach. FEMS Microbiology Reviews, (Sep. 2013), 37(5): 736-761.
[cited by applicant]
Clamp, J.R, et al. The Gastric Mucosal Barrier, Methods Find Exp Clin Pharmacol., (1989), 11 Suppl 1:19-25. Abstract Only.
[cited by applicant]
Werther, J.L., The gastric mucosal barrier. Mt Sinai J. Med., (Jan. 2000), 67 (1), 41-53. Abstract Only.
[cited by applicant]
Cited By (1)